Back to Search
Start Over
Deutsche says Novo data removes competitive threat for Eli Lilly
- Source :
- The Fly. September 20, 2024
- Publication Year :
- 2024
-
Abstract
- Deutsche Bank analyst James Shin says the Phase 2a results from Novo Nordisk's (NVO) monlunabant 'look underwhelming' and 'remove the threat of a large well-capitalized, small-molecule competitor' to Eli Lilly's [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.809361686